Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis. (2020). SKIN The Journal of Cutaneous Medicine, 4(6), s100. https://doi.org/10.25251/skin.4.supp.100